Sangamo Pfizer announce phase 12 interim data for investigational hemophilia A gene therapy

Sangamo, Pfizer announce phase 1/2 interim data for investigational hemophilia A gene therapy

Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed. Based

More From BioPortfolio on "Sangamo, Pfizer announce phase 1/2 interim data for investigational hemophilia A gene therapy"